A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With nAMD
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With nAMD
A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Inclusion Criteria:
Main Exclusion Criteria:
Any previous treatment for neovascular AMD.
Clinically significant ocular disorders (other than neovascular AMD), which may interfere with assessment of BCVA, assessment of safety, or fundus imaging.
Any current (or history of a) social, psychological, or medical condition that precludes enrolment into the study.
Capital Federal, Ciudad Autonoma Buenos Aires C1120AAN, Argentina
Ciudad Autonoma de Buenos Aire, C1015ABO, Argentina
Goettigen, Lower Saxony 37075, Germany
Chandigarh, Punjab 160012, India
Daegu, Gyeongsangbuk-do 42415, South Korea